| Literature DB >> 31229883 |
Adam S Hogendorf1, Agata Hogendorf2, Rafał Kurczab2, Justyna Kalinowska-Tłuścik3, Piotr Popik2, Agnieszka Nikiforuk2, Martyna Krawczyk2, Grzegorz Satała2, Tomasz Lenda2, Joanna Knutelska4, Ryszard Bugno2, Jakub Staroń2, Wojciech Pietruś5, Mikołaj Matłoka6, Krzysztof Dubiel6, Rafał Moszczyński-Pętkowski6, Jerzy Pieczykolan6, Maciej Wieczorek6, Bogusław Pilarski7, Paweł Zajdel4, Andrzej J Bojarski2.
Abstract
A new strategy in the design of aminergic GPCR ligands is proposed - the use of aromatic, heterocyclic basic moieties in place of the evergreen piperazine or alicyclic and aliphatic amines. This hypothesis has been tested using a benchmark series of 5-HT6R antagonists obtained by coupling variously substituted 2-aminoimidazole moieties to the well established 1-benzenesulfonyl-1H-indoles, which served as the ligands cores. The crystallographic studies revealed that upon protonation, the 2-aminoimidazole fragment triggers a resonance driven conformational change leading to a form of higher affinity. This molecular switch may be responsible for the observed differences in 5-HT6R activity of the studied chemotypes with different amine-like fragments. Considering the multiple functionalization sites of the embedded guanidine fragment, diverse libraries were constructed, and the relationships between the structure and activity, metabolic stability, and solubility were established. Compounds from the N-(1H-imidazol-2-yl)acylamide chemotype (10a-z) exhibited high affinity for 5-HT6R and very high selectivity over 5-HT1A, 5-HT2A, 5-HT7 and D2 receptors (negligible binding), which was attributed to their very weak basicity. The lead compound in the series 4-methyl-5-[1-(naphthalene-1-sulfonyl)-1H-indol-3-yl]-1H-imidazol-2-amine (9i) was shown to reverse the cognitive impairment caused by the administration of scopolamine in rats indicating procognitive potential.Entities:
Keywords: 2-Aminoimidazole; 5-HT(6) antagonist; Alzheimer's disease; GPCR; Non-basic; Serotonin
Mesh:
Substances:
Year: 2019 PMID: 31229883 DOI: 10.1016/j.ejmech.2019.06.001
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514